Rocket Pharmaceuticals Rises After KRESLADI Approval Rocket Pharmaceuticals shares rose 22% on Mar 29, 2026 after FDA approval of KRESLADI; analysts project $250–$450m peak sales and a ~3,200 patient addressable market.

Rocket Pharmaceuticals Rises After KRESLADI Approval: Rocket Pharmaceuticals shares rose 22% on Mar 29, 2026 after FDA approval of KRESLADI; analysts project $250–$450m peak sales and a ~3,200 patient… 👈 Read full analysis #RocketPharmaceuticals #KRESLADI #FDAApproval #Pharmaceuticals #Biotech

Click Subscribe #RocketPharmaceuticals #FDALifted #ClinicalTrials #StockMarket #Pharmaceuticals

Click Subscribe #RocketPharmaceuticals #StockMarket #Investing #FDA #GeneTherapy